Tyme Technologies stock flies flies ahead of data release on SM-88 in fighting pancreatic cancer
Shares in Tyme Technologies Inc (NASDAQ:TYME) flew Tuesday after the New York-based clinical-stage biotechnology company said it will hold a conference call to discuss data from a Phase 2 clinical trial evaluating lead therapy SM-88 in battling pancreatic cancer.
The management team will hold a conference call with analysts and investors at 9 am EST on January 18 to discuss the SM-88 preliminary Phase 2 pancreatic cancer data.
This data will also be presented in four posters at the three-day Gastrointestinal Cancers symposium being organized by the American Society of Clinical Oncology, in San Francisco starting January 17.
Investors anticipating positive data sent shares of the biotech up 19.3% to $2.93.
READ: Lexaria Bioscience inks deal with Altria Ventures to develop reduced-risk nicotine products; shares soar
Tyme Technologies is developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress.
The biotech is developing SM-88, a novel combination therapy that utilizes a proprietary dysfunctional tyrosine derivative to interrupt the metabolic processes of cancer cells, breaking down the cells’ key defenses and making them vulnerable to oxidative stress and death.
Tyme said its SM-88 therapy has demonstrated “efficacy in the treatment of multiple oncology indications, including breast and prostate, and pancreatic cancer” without serious adverse events.
The SM-88 program is expected to enter a pivotal trial in metastatic pancreatic cancer during 2019.
Contact Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/212631/tyme-technologies-stock-flies-flies-ahead-of-data-release-on-sm-88-in-fighting-pancreatic-cancer-212631.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).